Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)

Dianthus Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $19.5 million for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 48.78% year-over-year to $19.5 million; the TTM figure through Dec 2025 stood at $19.5 million (up 48.78% YoY), while the FY2025 annual figure was $19.5 million, up 48.78% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $19.5 million, up from $16.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $19.5 million in Q4 2025, with the low at $1.6 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $7.4 million (2021), against an average of $8.5 million.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses sank 75.55% in 2023, then jumped 273.13% in 2024.
• Dianthus Therapeutics' Accumulated Expenses stood at $7.8 million in 2021, then fell by 15.53% to $6.6 million in 2022, then decreased by 1.57% to $6.5 million in 2023, then surged by 101.01% to $13.1 million in 2024, then jumped by 48.78% to $19.5 million in 2025.
• Business Quant data shows DNTH's Accumulated Expenses at $19.5 million in Q4 2025, $16.0 million in Q3 2025, and $14.0 million in Q2 2025.